

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

07 Jul 2026

### Comparison of the effect of Letrozole and medroxy progesterone on premenopausal patient with endometrial hyperplasia: Randomized Clinical Trial

#### Protocol summary

##### Summary

One of the most common reasons of abnormal uterine bleeding is endometrial hyperplasia, leading to infertility and increased risk of endometrial cancer. This is a non-blind randomized clinical trial. The study population included 80 women referred to Abolfazle Clinic. Patients were divided into two groups based on the table of random numbers. Trial phase is 2-3. The diagnosis of endometrial hyperplasia was confirmed by pathology (curettage). Pathology report was simple endometrial hyperplasia. Inclusion criteria in the study consist of childbearing age women; lack of pregnancy and existence of simple endometrial hyperplasia in pathology report. Exclusion criteria in this research include non-reproductive ages; pregnancy; existence of complex hyperplasia with atypia in pathology report. Interventional group (40 patients) was treated by letrozole through a dosage of one tablet per day over three months. Control group (40 patients) received 10 mg of medroxy progesterone from day 16 to 25 three-months. The patients were rechecked up after three and six months. Also Transvaginal sonography and endometrial curettage were performed to evaluate the endometrial status. This study was conducted over a 3-year period from 2012 to 2014. We studied the effect of letrozole on endometrial thickness as well as reduction of irregular bleeding.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201510244339N12**  
Registration date: **2015-12-04, 1394/09/13**  
Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2015-12-04, 1394/09/13

##### Registrant information

###### Name

Elham Rahmani

###### Name of organization / entity

Bushehr University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 77125265914

###### Email address

rahmani@bpums.ac.ir

##### Recruitment status

###### Recruitment complete

##### Funding source

Bushehr University of Medical Sciences

##### Expected recruitment start date

2012-04-27, 1391/02/08

##### Expected recruitment end date

2014-09-21, 1393/06/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Comparison of the effect of Letrozole and medroxy progesterone on premenopausal patient with endometrial hyperplasia: Randomized Clinical Trial

##### Public title

Letrozole in increasing endometrial thickness in Premenopausal patient

## Purpose

Treatment

## Inclusion/Exclusion criteria

Inclusion criteria: women of reproductive age; non-pregnant; the diagnosis of endometrial hyperplasia as ultrasound and pathology. Exclusion criteria: side effects of letrozole; the prohibition of medicine prescription.

## Age

From **18 years** old to **50 years** old

## Gender

Female

## Phase

2-3

## Groups that have been masked

*No information*

## Sample size

Target sample size: **80**

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Not blinded

## Blinding description

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Bushehr University of Medical Sciences

##### Street address

Bushehr University of Medical Sciences, Alamdar St,  
Salman Farsi St, Bushehr, Iran.

##### City

Bushehr

##### Postal code

#### Approval date

2011-04-28, 1390/02/08

#### Ethics committee reference number

3827

## Health conditions studied

### 1

#### Description of health condition studied

Endometrial hyperplasia

#### ICD-10 code

N85.0

#### ICD-10 code description

Endometrial glandular hyperplasia

## Primary outcomes

### 1

#### Description

The effect of letrozole on endometrial thickness

#### Timepoint

Three months and six months

#### Method of measurement

Transvaginal sonography

## Secondary outcomes

### 1

#### Description

Reduction of irregular bleeding.

#### Timepoint

Three months and six months

#### Method of measurement

History of the patients

## Intervention groups

### 1

#### Description

Control group (40 patients) received 10 mg of medroxy progesterone from day 16 to 25 three-months. The patients were rechecked up after three and six months. Also Transvaginal sonography and endometrial curettage were performed to evaluate the endometrial status.

#### Category

Treatment - Drugs

### 2

#### Description

Interventional group (40 patients) was treated by letrozole through a dosage of one tablet (2.5mg) per day over three months. The patients were rechecked up after three and six months. Also Transvaginal sonography and endometrial curettage were performed to evaluate the endometrial status.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Persian Gulf Martyrs Hospital

##### Full name of responsible person

Dr Elham Rahmani

##### Street address

Persian Gulf Martyrs Hospital, Borj square, Borj Blvd.

##### City

Bushehr

## Sponsors / Funding sources

1

### Sponsor

**Name of organization / entity**

Vice chancellor of research, Bushehr University of Medical Sciences

**Full name of responsible person**

Dr Afshin Ostovar

**Street address**

Bushehr University of Medical Sciences, Alamdar St, Salman Farsi St, Bushehr, Iran.

**City**

Bushehr

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice chancellor of research, Bushehr University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

*empty*

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Bushehr University of Medical Sciences

**Full name of responsible person**

Dr Elham Rahmani

**Position**

Associate professor

**Other areas of specialty/work****Street address**

Martyrs Hospital in Persian Gulf, Taleghani Street, Azadi Square, Bushehr, Iran

**City**

Bushehr

**Postal code****Phone**

+98 77333455374

**Fax****Email**

rahmani@bpums.ac.ir

**Web page address**

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Bushehr University of medical Sciences

**Full name of responsible person**

Dr Elham Rahmani

**Position**

Associate professor

**Other areas of specialty/work****Street address**

Martyrs Hospital in Persian Gulf, Taleghani Street, Azadi Square, Bushehr, Iran

**City**

Bushehr

**Postal code****Phone**

+98 77 3345 5374

**Fax****Email**

rahmani@bpums.ac.ir

**Web page address**

## Person responsible for updating data

**Contact**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*